Tag: atopic dermatitis (AD)

June 28, 2019 Off

Dupixent gets extended use for certain atopic dermatitis in adolescents

By Dino Mustafić

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has nodded for extension for Dupixent, following USFDA’s approval for nasal polyposis, enabling its approval in the European Union (EU) to also include adolescents 12 to 17 years of age with moderate-to-severe AD who are candidates for systemic therapy.